Publication details

Ranibizumab v léčbě věkem podmíněné makulární degenerace

Title in English Ranibizumab in treatment of age-related macular degeneration
Authors

MATUŠKOVÁ Veronika

Year of publication 2014
Type Article in Periodical
Magazine / Source Farmakoterapie
MU Faculty or unit

Faculty of Medicine

Citation
Field ORL, ophthalmology, stomatology
Keywords ranibizumab; treatment; wet form of age-related macular degeneration; diabetic macular oedema; retinal vein occlusion
Description Ranibizumab is a fragment of a recombinant humanized monoclonal antibody against vascular endothelial growth factor. Its action results in reduced proliferation of endothelial cells, reduced vascular permeability, and it stops the formation of new vessels. Ranibizumab is indicated for intravitreal treatment of wet age-related macular degeneration, in the treatment of diabetic macular oedema, and macular edema (ME) caused by retinal vein occlusion for the treatment of choroidal neovascularization (CNV) secondary to pathological myopia (PM).

You are running an old browser version. We recommend updating your browser to its latest version.

More info